Bioinformatics, Convergence Science, and Systems Biology最新文献

筛选
英文 中文
Abstract 910: The cBioPortal for cancer genomics 摘要910:癌症基因组学的基因门户网站
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.am2019-910
Jianjiong Gao, T. Mazor, Adam Abeshouse, Ersin Ciftci, I. Bruijn, Benjamin E. Gross, Karthik Kalletla, P. Kumari, Ritika Kundra, James Lindsay, Aaron Lisman, Pieter Lukasse, Ramyasree Madupuri, Angelica Ochoa, Oleguer Plantalech, P. Raman, F. Schaeffer, R. Sheridan, Jing Su, S. O. Sumer, Yichao Sun, Sander C Tan, Sjoerd van Hagen, Avery Wang, Manda Wilson, Hongxin Zhang, Gaofei Zhao, Kelsey Zhu, K. V. Bochove, U. Dogrusoz, Trevor J Pugh, A. Resnick, C. Sander, E. Cerami, N. Schultz
{"title":"Abstract 910: The cBioPortal for cancer genomics","authors":"Jianjiong Gao, T. Mazor, Adam Abeshouse, Ersin Ciftci, I. Bruijn, Benjamin E. Gross, Karthik Kalletla, P. Kumari, Ritika Kundra, James Lindsay, Aaron Lisman, Pieter Lukasse, Ramyasree Madupuri, Angelica Ochoa, Oleguer Plantalech, P. Raman, F. Schaeffer, R. Sheridan, Jing Su, S. O. Sumer, Yichao Sun, Sander C Tan, Sjoerd van Hagen, Avery Wang, Manda Wilson, Hongxin Zhang, Gaofei Zhao, Kelsey Zhu, K. V. Bochove, U. Dogrusoz, Trevor J Pugh, A. Resnick, C. Sander, E. Cerami, N. Schultz","doi":"10.1158/1538-7445.am2019-910","DOIUrl":"https://doi.org/10.1158/1538-7445.am2019-910","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121662805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 1633: Pretreatment prediction of recurrence-free survival in hepatocellular carcinoma after surgical resection by machine-learning based imaging analysis [摘要]基于机器学习的影像学分析对肝细胞癌术后无复发生存的预处理预测
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.AM2019-1633
Jingwei Wei, Yuqi Han, Xia Wu, Yushen Jin, Jie Tian
{"title":"Abstract 1633: Pretreatment prediction of recurrence-free survival in hepatocellular carcinoma after surgical resection by machine-learning based imaging analysis","authors":"Jingwei Wei, Yuqi Han, Xia Wu, Yushen Jin, Jie Tian","doi":"10.1158/1538-7445.AM2019-1633","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-1633","url":null,"abstract":"In hepatocellular carcinoma (HCC), patients at early stages are recommended to accept surgical resection as primary treatment by internationally endorsed guidelines. Nevertheless, post-surgical recurrence is one of the main threats that lead to death, with 5-year recurrence rate of over 70%. How to select patients at high risk of recurrence is essential to guide systematic follow-up and provide basis for alternative treatment strategy making, thus to prolong overall survival. In this study, we aimed to predict recurrence free survival (RFS) for HCC patients undergoing surgical resection using MR-based radiomics analysis. A cohort of 176 patients diagnosed with HCC was enrolled with complete recurrence follow-ups. A total of 4404 radiomic features including shape and size, intensity, textural, and wavelet features were extracted on the segmented tumor lesion. Mutual correlation among the features were initially assessed to reduce redundant features by Pearson’s correlation analysis. Lasso-cox regression modeling was further applied to select recurrence-related key features and generate the radiomics signature with 10-fold cross validation. In addition, we explored the predictive ability of conventional clinical factors as comparable predictors with radiomics signature by univariate analysis and constructed clinical model by cox proportional hazard regression modeling. The result turned out that 4 T2WI-based radiomic features were identified as most correlated predictors for the recurrence prediction modeling, which were correspondingly gabor10_glszm_SZLGE, gabor12_glcm45_cluster_prominence, W5L5_fos_kurtosis, and W5E5_fos_skewness. The radiomics signature could successfully stratify patients into high-risk and low-risk groups with p-value 0.05 in both training and validation cohorts. Our study revealed T2WI-based archetypal radiomic features related with RFS and highlighted the radiomics model as an effective noninvasive tool for RFS pretreatment prediction in HCC after surgical resection, which would beyond doubt provide reliable basis for individualized treatment decision making in HCC management. Citation Format: Jingwei Wei, Yuqi Han, Xia Wu, Yushen Jin, Jie Tian. Pretreatment prediction of recurrence-free survival in hepatocellular carcinoma after surgical resection by machine-learning based imaging analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1633.","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122479771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 694: Mathematical modeling of stromal fibroblast-mediated adaptive resistance to bortezomib in multiple myeloma 694:间质成纤维细胞介导的多发性骨髓瘤对硼替佐米适应性耐药的数学模型
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.SABCS18-694
Elliot Eton, K. Kaveh, Sachin K. Khiste, A. Fernandes, A. Agarwal, Shiladitya Sengupta, A. Goldman
{"title":"Abstract 694: Mathematical modeling of stromal fibroblast-mediated adaptive resistance to bortezomib in multiple myeloma","authors":"Elliot Eton, K. Kaveh, Sachin K. Khiste, A. Fernandes, A. Agarwal, Shiladitya Sengupta, A. Goldman","doi":"10.1158/1538-7445.SABCS18-694","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-694","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"72 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131369799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 686: Quantitative analysis of the role of homologous recombination in response to radiotherapy for prostate cancer 686:定量分析同源重组在前列腺癌放疗应答中的作用
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.SABCS18-686
M. Qian, A. Almasan, Evren Gurkan-Cavusoglu
{"title":"Abstract 686: Quantitative analysis of the role of homologous recombination in response to radiotherapy for prostate cancer","authors":"M. Qian, A. Almasan, Evren Gurkan-Cavusoglu","doi":"10.1158/1538-7445.SABCS18-686","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-686","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"102 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127567605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 687: Implementation of inter-patient variability in semi-mechanistic model of melanoma treatment with vemurafenib 687: vemurafenib治疗黑色素瘤半机制模型中患者间变异性的实现
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.SABCS18-687
Dmitry Shchelokov, O. Demin
{"title":"Abstract 687: Implementation of inter-patient variability in semi-mechanistic model of melanoma treatment with vemurafenib","authors":"Dmitry Shchelokov, O. Demin","doi":"10.1158/1538-7445.SABCS18-687","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-687","url":null,"abstract":"Introduction : The number of parameters in quantitative systems pharmacology (QSP), mechanistic and semi-mechanistic models is greater than in conventional PK/PD models. That is why it is not possible to implement inter-patient variability using only clinical data. The objective of this study was to describe inter-patient variability in the semi-mechanistic model of melanoma treatment with vemurafenib, a BRAF inhibitor, on the basis of published human in vitro, in vivo and clinical data, and to predict overall response from phase 2 clinical trial. Methods : Model described melanoma progression and its treatment with vemurafenib. It includes (i) proliferation, apoptosis, and transition between states (c-MET negative/positive and sensitive/resistant to BRAF inhibitor) of cancer cells; (ii) HGF effect on proliferation of melanoma cells; (iii) PK/PD of vemurafenib. Various types of data were used to extract inter-patient variability, for example: (a) in vitro data on effect of vemurafenib on melanoma cell lines [1]; (b) in vivo data on tumor growth in melanoma patients without treatment [2]; (c) in vivo data on HGF level in blood plasma of melanoma patients [3]. Results : Different virtual patients developed by the model reproduce all types of tumor response to vemurafenib monotherapy according to RECIST criteria: complete response, partial response, stable disease and progressive disease. To evaluate the predictive ability of the model in a quantitative manner we compared results of simulation of virtual patients population with clinical outcomes. An overall response rate was 70% in the model versus 53% (95% CI, 44 to 62) observed in phase 2 clinical trial [4]. Overestimation can be explained by intermittent administration and dose reduction in case of adverse events in clinical trials which were not taken into account in the model. Conclusions : Our work establishes the benefit of using of in vitro and in vivo data in addition to clinical data to predict the variability in treatment outcomes of cancer patients. [1] Stones et al. Front Genet. 2013 May 8;4:66 [2] Hartung et al. PLoS One. 2017 May 4;12(5):e0176080 [3] Hugel et al. Melanoma Res. 2016 Aug;26(4):354-60 [4] Sosman et al. N Engl J Med. 2012 Feb 23;366(8):707-14 Citation Format: Dmitry Shchelokov, Oleg Demin Jr, Oleg Demin. Implementation of inter-patient variability in semi-mechanistic model of melanoma treatment with vemurafenib [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 687.","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134284085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 2452: Patient segmentation using machine-learning based literature and genomic data synthesis uncovers novel cohorts of NSCLC and mesothelioma patients 2452:使用基于机器学习的文献和基因组数据合成的患者分割揭示了NSCLC和间皮瘤患者的新队列
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.SABCS18-2452
E. Garcia-Rivera, A. Mansfield, K. Murugadoss, Murali Aravamudan
{"title":"Abstract 2452: Patient segmentation using machine-learning based literature and genomic data synthesis uncovers novel cohorts of NSCLC and mesothelioma patients","authors":"E. Garcia-Rivera, A. Mansfield, K. Murugadoss, Murali Aravamudan","doi":"10.1158/1538-7445.SABCS18-2452","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-2452","url":null,"abstract":"Current unbiased approaches to mine the large amounts of patient-level data on mutations, structural variations and gene expression result in an unwieldy amount of interactions and correlations, which cannot be parsed to identify disease drivers. Here we present an approach to encode mutational and structural variant data at a patient level in a semantic association space. This approach transforms the presence of a mutation (or other feature) in each patient into the quantitative semantic association score of the corresponding gene and the phenotype of interest, which we have trained on all publicly available literature using word-embedding neural networks. Using data from The Cancer Genome Atlas (TCGA), we encoded the mutation or structural variant status (incl. copy number, fusion and chromothripsis) of all patients in the Lung Adenocarcinoma and Mesothelioma cohorts into our semantic space. For each cancer, we first defined the set of genes that are most associated to it according to the literature. To project each patient into this semantic space, we next determined if each patient had a mutation in the genes representing the disease semantic vector (e.g. NSCLC). For TCGA data we only counted non-Silent mutations and represented them as a binary number for each gene, i.e. 0 if the patient had no mutations in that gene and 1 if the patient had a non-Silent mutation in the gene. Each patient was then encoded in a binary vector with each member corresponding to a gene from the disease semantic vector. For example, lung adenocarcinoma was associated to 1,367 genes in our semantic space. A lung adenocarcinoma patient’s vector would them be composed of 1,367 binary numbers dictating if the gene is mutated or not in that patient. We then multiply these binary vectors with the semantic disease vector to obtain the patient’s projection in the disease space, which in effect replaces the binary number with the Semantic Association Score between the gene and the disease. Contrary to clustering patient samples by their mutation or structural variant data alone, our projected patient vectors clustered patients together into 22 groups with high patient-to-patient similarity. These clusters recapitulate canonical knowledge about the disease, e.g. Lung Adenocarcinoma patients form clusters that include EGFR-driven and KRAS-driven cohorts. We also see novel groups of patients driven by genes such as MET, STK11 and MALAT1. These clusters can be further stratified by their survival status and other clinical features. We validated our approach with a non-TCGA Mesothelioma cohort, revealing similarities in patient stratification regardless of the data source. This approach represents a dramatic shift in patient segmentation, delivering real-time grouping of patients and biomarker identification, which can accelerate clinical trial design and therapeutic development strategy. Citation Format: Enrique Garcia-Rivera, Aaron S. Mansfield, Karthik Murugadoss, Murali Ara","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"446 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134271646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 679: Quantitative systems pharmacology modeling of immunotherapies in B-cell acute lymphoblastic leukemia 679: b细胞急性淋巴细胞白血病免疫治疗的定量系统药理学模型
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.SABCS18-679
O. Demin, A. Nikitich
{"title":"Abstract 679: Quantitative systems pharmacology modeling of immunotherapies in B-cell acute lymphoblastic leukemia","authors":"O. Demin, A. Nikitich","doi":"10.1158/1538-7445.SABCS18-679","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-679","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"166 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134412560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 1643: Discovery pipeline of cancer transcriptomic biomarkers using machine learning 1643:利用机器学习发现癌症转录组生物标志物
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.AM2019-1643
Eileen S Kim
{"title":"Abstract 1643: Discovery pipeline of cancer transcriptomic biomarkers using machine learning","authors":"Eileen S Kim","doi":"10.1158/1538-7445.AM2019-1643","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-1643","url":null,"abstract":"Introduction: Cancer affects millions of people and causes nearly 1 in 6 deaths worldwide. Precision oncology holds potential in guiding cancer treatment on a molecular basis and elucidating targetable cancer pathways. This study aims to create a discovery pipeline that uses cancer patients’ transcriptomes and machine learning algorithms to predict cancer patient survival. Methods: Transcriptomic and phenotypic data from cancer patients were downloaded from The Cancer Genome Atlas (TCGA). Initial genes were selected using univariate cox proportional hazard models to predict overall survival across all cancer types. Co-expressed selected genes were clustered, creating gene sets per cancer subtype. Then, an amalgam of LASSO and elastic-net regularized generalized linear models (GLMNET), gene bootstrapping, random forest without/with shadow features (Boruta), and recursive feature elimination were used. Monte Carlo iterations were performed for GLMNET to assess model stability and over-/underfitting. Results: The highest hazard ratios (HRs) and lowest p-values resulted from the univariate cox proportional hazards model (e.g. for the RASGEF1A gene in a uterine serous carcinoma model, HR=2.8e8, p=0.005) and subsequent GLMNET models (e.g. 392 genes for uterine endometrioid carcinoma, HR=2.89e8, p=0.00873). Boruta before GLMNET yielded lower HRs and higher p-values (e.g. 11 genes for uterine serous carcinoma, HR=2, p=0.0517). Bootstrapping genes before GLMNET generally yielded much lower HRs and higher p-values. Conclusions: We were able to model survival risk in cancer patients with a variety of methods. The best method so far is univariate gene selection and GLMNET, although random forest is promising. Next steps include exploring random forest models further, investigating the biology of prognostic models, using disease-specific survival, analyzing possible confounders, using Breslow-Wilcoxon or accelerated failure time models, replacing histological with molecular-signature-based cancer subtypes, and exploring alternative methods for prognosis prediction. Supported by the Medical Scholars Program, Medical College of Georgia, Augusta, GA. Citation Format: Eileen Kim. Discovery pipeline of cancer transcriptomic biomarkers using machine learning [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1643.","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114389861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 1661: Molecular modeling of an emerging chemopreventive agent wedelolactone against multiple targets in oncogenetic pathway 摘要/ Abstract摘要:新兴化学预防药物维德内酯在肿瘤发生途径中对抗多靶点的分子模型研究
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.AM2019-1661
S. Sarwar, Tauqeer Ahmed, J. Yu, F. Huq
{"title":"Abstract 1661: Molecular modeling of an emerging chemopreventive agent wedelolactone against multiple targets in oncogenetic pathway","authors":"S. Sarwar, Tauqeer Ahmed, J. Yu, F. Huq","doi":"10.1158/1538-7445.AM2019-1661","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-1661","url":null,"abstract":"Targeting multiple pathways involved either in drug resistance or/and in intact cancer cell survival are promising strategies. Epigenetics is being immensely recognized as exciting frontier in cancer research. Kinases have direct and indirect epigenetic impacts. Kinases are among the popular discovery targets and kinase inhibitors represent one of the key classes of drugs in the last two decades of oncology research. Braf kinases and cyclin dependent protein kinases exert their role as key mediators of signal transduction, apoptosis and overall intercellular communications. Topoisomerase II inhibitors including etoposide, tinoposide are important drugs used in breast cancer, sarcomas and lymphomas while inhibitors of dihydrofolatereductase, a key enzyme in the synthesis of DNA, are also clinically useful antagonists/inhibitors of ERα and aromatases have the potential to be therapeutically significant towards estrogen mediated breast, ovarian and uterine (endometrium) cancers. Wedelolactone is emerging as a small molecule with cytotoxic potential. Auto Dock Vina program was used for docking study .Affinity of best docked pose of ligand and protein target complex was determined by E-value (Kcal/mol).3D-structures of target proteins were taken from http://www.rcsb.org/pdb/home/home.do. The target proteins include dihydrofolatereductase, braf kinase, cyclin dependent protein kinase, nuclear factor kappa b, topoisomerase II, aromatase, estrogen receptor alpha and alkaline phosphatase (PDB ID: 2C2T, PDB ID: 3Q4C, PDB ID: 1HCL, PDB ID: 1NFK, PDB ID: 5B58, PDB ID: 3S7S, PDB ID: 3ERT, PDB ID: 1ANI). The structures (wedelolactone and standard drugs) were downloaded in.xml format and converted to PDB format via Open Babel JUI software. PDB form of wedelolactone, EGCG, reference drugs and target proteins were converted to PDBQT via AutoDock Tools (Version1.5.6 Sep_17_14). Discovery studio visualizer was used for post docking interactions for number of Hydrogen bonds (classical and non-classical), π-π bonds and other hydrophobic interactions by binding amino acid residues. The cell survival fraction was determined using the MTT reduction assay. The order of binding affinity of wedelolactone was found as: estrogen receptor alpha >dihydrofolate reductase>braf kinase > topoisomerase II > CDPK > aromatase > alkaline phosphatase >Nfkb. We identified wedelolactone as a cytotoxic agent in breast and ovarian tumor models with the potential to inhibit multiple targets in oncogenic as depicted through its In-silico study. Further research should be encouraged to investigate different aspects of wedelolactone. Note: This abstract was not presented at the meeting. Citation Format: sadia sarwar, Tauqeer Ahmed, Jun Q. Yu, Fazlul Huq. Molecular modeling of an emerging chemopreventive agent wedelolactone against multiple targets in oncogenetic pathway [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, ","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115749774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abstract 1654: Detection of structural variations in a cancer reference sample with multiple NGS platforms 摘要1654:利用多个NGS平台检测癌症参考样本的结构变异
Bioinformatics, Convergence Science, and Systems Biology Pub Date : 2019-07-01 DOI: 10.1158/1538-7445.SABCS18-1654
Yongmei Zhao, Wenming Xiao
{"title":"Abstract 1654: Detection of structural variations in a cancer reference sample with multiple NGS platforms","authors":"Yongmei Zhao, Wenming Xiao","doi":"10.1158/1538-7445.SABCS18-1654","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-1654","url":null,"abstract":"","PeriodicalId":445323,"journal":{"name":"Bioinformatics, Convergence Science, and Systems Biology","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134287492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书